[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.220.238. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
December NaN, 2002

Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain

Arch Intern Med. 2002;162(22):2639. doi:

The 3 case-control studies by Drs Rahme, Solomon, Watson, and their colleagues13 published recently in the ARCHIVES suggest that the main reason for an increased risk of MI found for rofecoxib when compared with naproxen in the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial4 may be a cardioprotective effect of naproxen. We have 2 concerns with this interpretation.

First Page Preview View Large
First page PDF preview
First page PDF preview
×